No. RFA-MH-27-135 · National Institutes of Health
Addressing Methodological Challenges with Clinical Trials of Rapid-Acting Psychotropic Interventional Drugs (RAPIDs) (R01 Clinical Trial Required)
- Award range
- Not specified
- Expected awards
- ~5
- Application deadline
- Oct 11, 2026
- Posted
- Apr 29, 2026
- Last verified
- 3 days ago
At a glance
No plain-language summary yet for this grant — the official description below is the best source.
What it funds
Official description from grants.gov
The purpose of this notice of funding opportunity (NOFO) is to elucidate the key components of the therapeutic effects of rapid-acting psychotropic interventional drugs (RAPIDs) by addressing the methodological challenges involved with these clinical trials. In addition, this NOFO seeks to advance understanding of how RAPIDs and adjunctive psychosocial interventions can be optimally delivered, monitored, and sustained over time to enhance effectiveness and generalizability. The NOFO will support studies designed to enhance the rigor of RAPID clinical trial design, which will ultimately increase the interpretability of the data and the generalizability of the results.
Who can apply
- City or township governments
- County governments
- For-profit organizations other than small businesses
- Independent school districts
- Native American tribal governments (Federally recognized)
- Native American tribal organizations (other than Federally recognized)
- Nonprofits with 501(c)(3) status (other than higher education)
- Nonprofits without 501(c)(3) status (other than higher education)
- Others
- Private institutions of higher education
- Public and State controlled institutions of higher education
- Public housing authorities / Indian housing authorities
- Small businesses
- Special district governments
- State governments
Program history
USASpending.govAssistance listing 93.242 · Mental Health Research Grants
Real awards this federal program has made — the whole assistance listing (93.242), not just this notice.
| Fiscal year | Awards | Median award | Middle half |
|---|---|---|---|
| FY 2026 (so far) | 491 | $451,000 | $167,702 – $811,948 |
| FY 2025 | 600 | $731,738 | $320,544 – $1,460,736 |
| FY 2024 | 883 | — | — |
| FY 2023 | 898 | — | — |
| FY 2022 | 986 | — | — |
| FY 2021 | 945 | — | — |
Dollar figures are based on the 1,000 most recent awards we store, not all 4,803 — award counts are complete.
- MASSACHUSETTS INSTITUTE OF TECHNOLOGY $21,714,815 · FY 2025
- OHIO STATE UNIVERSITY, THE $19,515,757 · FY 2025
- ALBERT EINSTEIN COLLEGE OF MEDICINE $18,270,924 · FY 2025
- DUKE UNIVERSITY $15,039,330 · FY 2025
- ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI $12,007,972 · FY 2026
Source: USASpending.gov · refreshed Aug 6, 2026
Assistance listing 93.279 · Drug Use and Addiction Research Programs
Real awards this federal program has made — the whole assistance listing (93.279), not just this notice.
| Fiscal year | Awards | Median award | Middle half |
|---|---|---|---|
| FY 2026 (so far) | 428 | $422,523 | $183,034 – $700,682 |
| FY 2025 | 588 | $709,054 | $348,214 – $1,489,059 |
| FY 2024 | 714 | — | — |
| FY 2023 | 724 | — | — |
| FY 2022 | 740 | — | — |
| FY 2021 | 606 | — | — |
Dollar figures are based on the 1,000 most recent awards we store, not all 3,800 — award counts are complete.
- FLORIDA INTERNATIONAL UNIVERSITY $7,372,834 · FY 2025
- BETH ISRAEL DEACONESS MEDICAL CENTER, INC. $7,081,684 · FY 2025
- UNIVERSITY OF WASHINGTON $7,003,822 · FY 2025
- REACX PHARMACEUTICALS, INC. $6,900,000 · FY 2025
- WORCESTER POLYTECHNIC INSTITUTE $6,889,914 · FY 2025
Source: USASpending.gov · refreshed Aug 18, 2026